[pharmaceutical hq]
CEO: we need some new drug names
MKTG GUY: cymbalta fabhalta veozah
VP: ar-are you ok
MKTG GUY: kisqali austedo phexxi
VP: sir he’s having a stroke
MKTG GUY: xgeva toujeo zeposia
VP: we should call 911
MKTG GUY: xeljanz opdivo wegovy
CEO: *writing* now let’s not be hasty
CEO: we need some new drug names
MKTG GUY: cymbalta fabhalta veozah
VP: ar-are you ok
MKTG GUY: kisqali austedo phexxi
VP: sir he’s having a stroke
MKTG GUY: xgeva toujeo zeposia
VP: we should call 911
MKTG GUY: xeljanz opdivo wegovy
CEO: *writing* now let’s not be hasty
June 6, 2025 at 3:26 PM
[pharmaceutical hq]
CEO: we need some new drug names
MKTG GUY: cymbalta fabhalta veozah
VP: ar-are you ok
MKTG GUY: kisqali austedo phexxi
VP: sir he’s having a stroke
MKTG GUY: xgeva toujeo zeposia
VP: we should call 911
MKTG GUY: xeljanz opdivo wegovy
CEO: *writing* now let’s not be hasty
CEO: we need some new drug names
MKTG GUY: cymbalta fabhalta veozah
VP: ar-are you ok
MKTG GUY: kisqali austedo phexxi
VP: sir he’s having a stroke
MKTG GUY: xgeva toujeo zeposia
VP: we should call 911
MKTG GUY: xeljanz opdivo wegovy
CEO: *writing* now let’s not be hasty
دوستان یه آمپول Xgeva 120 mg هست که میدونم سخت گیر میاد، تا برج ۹ سال ۲۰۲۴ اعتبار داره. اگر کسی رو میشناسید که به این دارو نیاز داره لطفا معرفی کنید.
December 12, 2023 at 8:54 PM
دوستان یه آمپول Xgeva 120 mg هست که میدونم سخت گیر میاد، تا برج ۹ سال ۲۰۲۴ اعتبار داره. اگر کسی رو میشناسید که به این دارو نیاز داره لطفا معرفی کنید.
#Medsky🧪#pharmasky
@fda.gov approves second biosimilars to #Prolia & #Xgeva ( #denosumab) Denosumab is a type of targeted Drug #monoclonalantibody. It is for secondary bone cancer Tx . bnf.nice.org.uk/drugs/denosu...
www.accessdata.fda.gov/drugsatfda_d...
@fda.gov approves second biosimilars to #Prolia & #Xgeva ( #denosumab) Denosumab is a type of targeted Drug #monoclonalantibody. It is for secondary bone cancer Tx . bnf.nice.org.uk/drugs/denosu...
www.accessdata.fda.gov/drugsatfda_d...
February 14, 2025 at 9:30 PM
#Medsky🧪#pharmasky
@fda.gov approves second biosimilars to #Prolia & #Xgeva ( #denosumab) Denosumab is a type of targeted Drug #monoclonalantibody. It is for secondary bone cancer Tx . bnf.nice.org.uk/drugs/denosu...
www.accessdata.fda.gov/drugsatfda_d...
@fda.gov approves second biosimilars to #Prolia & #Xgeva ( #denosumab) Denosumab is a type of targeted Drug #monoclonalantibody. It is for secondary bone cancer Tx . bnf.nice.org.uk/drugs/denosu...
www.accessdata.fda.gov/drugsatfda_d...
Die gute Nachricht: Ich hab’s mir nicht eingebildet. Die schlechte: Fuß wieder gebrochen, vier bis sechs Wochen ruhigstellen, XGeva wohl erneut aussetzen. Lecko mio. 🤬
July 24, 2025 at 3:32 PM
Die gute Nachricht: Ich hab’s mir nicht eingebildet. Die schlechte: Fuß wieder gebrochen, vier bis sechs Wochen ruhigstellen, XGeva wohl erneut aussetzen. Lecko mio. 🤬
🚨 BREAKING: #$TEVA just won FDA approval for DEGEVMA, a biosimilar to Xgeva for treating bone complications in advanced cancer patients. 5 analysts have rated it in the past year, all at buy, with targets from $42 to $50.
September 28, 2026 at 8:17 PM
🚨 BREAKING: #$TEVA just won FDA approval for DEGEVMA, a biosimilar to Xgeva for treating bone complications in advanced cancer patients. 5 analysts have rated it in the past year, all at buy, with targets from $42 to $50.
Yes. I've been getting Xgeva since 2013 when I was first diagnosed De Novo.
April 12, 2025 at 1:46 PM
Yes. I've been getting Xgeva since 2013 when I was first diagnosed De Novo.
Amgen and Accord Settle Prolia® / Xgeva® BPCIA Litigation over INTP23
Amgen and Accord Settle Prolia® / Xgeva® BPCIA Litigation over INTP23
On July 16, 2025, Amgen and Accord settled Case No. 1:25-cv-01305 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) alleging infringement of 34 of Amgen’s...
www.jdsupra.com
July 30, 2025 at 4:47 PM
Amgen and Accord Settle Prolia® / Xgeva® BPCIA Litigation over INTP23
Hey there! I’ve got bone mets, too. What meds are you on? I’m doing the Kisqali/Faslodex/Xgeva combo since July
November 18, 2024 at 6:23 AM
Hey there! I’ve got bone mets, too. What meds are you on? I’m doing the Kisqali/Faslodex/Xgeva combo since July
Have they set you up with Xgeva shots? I'm MBC with mets in my sternum, ribs, and a small spot in my spine.
I started Xgeva "my old lady bone shot" a few years ago to help keep calcium in my bones after I broke a rib in three places just from bending over. It helps a ton.
I started Xgeva "my old lady bone shot" a few years ago to help keep calcium in my bones after I broke a rib in three places just from bending over. It helps a ton.
April 12, 2025 at 12:33 PM
Have they set you up with Xgeva shots? I'm MBC with mets in my sternum, ribs, and a small spot in my spine.
I started Xgeva "my old lady bone shot" a few years ago to help keep calcium in my bones after I broke a rib in three places just from bending over. It helps a ton.
I started Xgeva "my old lady bone shot" a few years ago to help keep calcium in my bones after I broke a rib in three places just from bending over. It helps a ton.
One day at a time. My husband is dealing with metastatic prostate cancer with mets to the spine, shoulder blades and lung. It’s being controlled with chemo and steroid injections, along with xgeva to strengthen the bones. It’s under control, never cured, but his PSA went from 448 to undetectable!
May 19, 2025 at 4:38 PM
One day at a time. My husband is dealing with metastatic prostate cancer with mets to the spine, shoulder blades and lung. It’s being controlled with chemo and steroid injections, along with xgeva to strengthen the bones. It’s under control, never cured, but his PSA went from 448 to undetectable!
Blog on a new clinical trial for people with established #T1D #type1diabetes:
cureresearch4type1diabetes.blogspot.com/2025/01/deno...
cureresearch4type1diabetes.blogspot.com/2025/01/deno...
Denosumab Starts A Phase-I Trial In People With Established T1D
Denosumab is a monoclonal antibody, which is already approved for several bone related diseases and is sold under the names Wyost, Xgeva, Pr...
cureresearch4type1diabetes.blogspot.com
January 31, 2025 at 10:27 PM
Blog on a new clinical trial for people with established #T1D #type1diabetes:
cureresearch4type1diabetes.blogspot.com/2025/01/deno...
cureresearch4type1diabetes.blogspot.com/2025/01/deno...
Biosimilaires : Xgeva et Prolia officiellement substituables en pharmacie !
www.revuepharma.fr/2026/09/xgev...
www.revuepharma.fr/2026/09/xgev...
Xgeva et Prolia officiellement substituables ! - Revue Pharma
Un arrêté publié au JO vient élargir à 13 la liste des groupes biologiques similaires pouvant donner lieu à une substitution en officine.
www.revuepharma.fr
September 22, 2026 at 10:24 AM
Biosimilaires : Xgeva et Prolia officiellement substituables en pharmacie !
www.revuepharma.fr/2026/09/xgev...
www.revuepharma.fr/2026/09/xgev...
Accord Announces Commercial Launch of Prolia® / Xgeva® Interchangeable Biosimilars Osvyrti® / Jubereq® (denosumab-desu)
Accord Announces Commercial Launch of Prolia® / Xgeva® Interchangeable Biosimilars Osvyrti® / Jubereq® (denosumab-desu)
On July 23, 2026, Accord BioPharma announced the commercial launch of Osvyrti® / Jubereq® (denosumab-desu), interchangeable biosimilars of...
www.jdsupra.com
August 10, 2026 at 6:38 PM
Accord Announces Commercial Launch of Prolia® / Xgeva® Interchangeable Biosimilars Osvyrti® / Jubereq® (denosumab-desu)
Accord Announces Commercial Launch of Prolia® / Xgeva® Interchangeable Biosimilars Osvyrti® / Jubereq® (denosumab-desu)
Accord Announces Commercial Launch of Prolia® / Xgeva® Interchangeable Biosimilars Osvyrti® / Jubereq® (denosumab-desu)
On July 23, 2026, Accord BioPharma announced the commercial launch of Osvyrti® / Jubereq® (denosumab-desu), interchangeable biosimilars of...
www.jdsupra.com
August 10, 2026 at 6:38 PM
Accord Announces Commercial Launch of Prolia® / Xgeva® Interchangeable Biosimilars Osvyrti® / Jubereq® (denosumab-desu)
Accord Announces Commercial Launch of Prolia® / Xgeva® Interchangeable Biosimilars Osvyrti® / Jubereq® (denosumab-desu)
Accord Announces Commercial Launch of Prolia® / Xgeva® Interchangeable Biosimilars Osvyrti® / Jubereq® (denosumab-desu)
On July 23, 2026, Accord BioPharma announced the commercial launch of Osvyrti® / Jubereq® (denosumab-desu), interchangeable biosimilars of...
www.jdsupra.com
August 10, 2026 at 6:38 PM
Accord Announces Commercial Launch of Prolia® / Xgeva® Interchangeable Biosimilars Osvyrti® / Jubereq® (denosumab-desu)
Drejtori i Klinikës konfirmoi se ka mungesë të përkohshme për shkak të problemeve në furnizimet
Onkologjia e Shkupit mbetet pa 3 terapi për kancerin
SHKUP — Pacientët ankohen se në Klinikën Universitare për Radioterapi dhe Onkologji mungojnë terapitë Zoladex, Fulvestrant dhe Xgeva. Drejtori i Klinikës, Igor Stojkovski, ka konfirmuar se aktualisht ka mungesë të përkohshme për shkak të problemeve dhe vonesave në furnizimet nga distributorët.
Klinika është në komunikim të vazhdueshëm me ta dhe, sipas informacioneve të marra, ilaçet do të jenë sërish në dispozicion në një kohë sa më të shkurtër. Më herët, pacientët përmes grupeve në rrjetet sociale reaguan se mungojnë terapitë Zoladex, Fulvestrant dhe Xgeva, të cilat përdoren në trajtimin e llojeve të caktuara të kancerit të gjirit, si dhe te pacientët me sëmundje të përhapur në kocka.
Ata shprehën shqetësim se shtyrja e terapisë mund të ndikojë në rrjedhën e trajtimit, ndërsa sipas informacioneve të tyre, nga Klinika u ishte thënë se ilaçet priten të arrijnë gjatë javëve në vijim. Ndryshe, problemi me mungesën e terapive paraqitet vazhdimisht kohë pas kohe në Klinikën e Onkologjisë.
_Burim:_ Portalb.mk
_— Redaksia ZHURMA_
zhurma.press
July 30, 2026 at 8:25 AM
Drejtori i Klinikës konfirmoi se ka mungesë të përkohshme për shkak të problemeve në furnizimet
Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
Dr Reddy’s Laboratories has secured a major regulatory milestone with the European Commission granting marketing authorisation for AVT03, its biosimilar to denosumab used in osteoporosis treatment. The…
Dr Reddy’s Laboratories has secured a major regulatory milestone with the European Commission granting marketing authorisation for AVT03, its biosimilar to denosumab used in osteoporosis treatment. The…
Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
Dr Reddy’s Laboratories has secured a major regulatory milestone with the European Commission granting marketing authorisation for AVT03, its biosimilar to denosumab used in osteoporosis treatment. The approval covers all EU member states as well as Iceland, Liechtenstein and Norway under the European Economic Area framework.The company said AVT03 is a biosimilar version of Prolia and Xgeva, both widely prescribed for managing bone loss and fracture risk.
planetreporthub.com
November 24, 2025 at 1:41 PM
Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
Dr Reddy’s Laboratories has secured a major regulatory milestone with the European Commission granting marketing authorisation for AVT03, its biosimilar to denosumab used in osteoporosis treatment. The…
Dr Reddy’s Laboratories has secured a major regulatory milestone with the European Commission granting marketing authorisation for AVT03, its biosimilar to denosumab used in osteoporosis treatment. The…
Yesterday went in to get a simple shot of bone strengthening Xgeva do I don’t break my hip. Turns out I was due for some immunotherapy. So hard to keep track of things.
December 27, 2023 at 6:13 PM
Yesterday went in to get a simple shot of bone strengthening Xgeva do I don’t break my hip. Turns out I was due for some immunotherapy. So hard to keep track of things.
"Boryung launches Samsung Bioepis' bone cancer biosimilar with storage edge over Amgen's Xgeva"
#Caregiving #Healthcare #ElderCare #MedSky
#Caregiving #Healthcare #ElderCare #MedSky
Boryung launches Samsung Bioepis' bone cancer biosimilar with storage edge over Amgen's Xgeva
Boryung has officially launched Xbryk, a denosumab biosimilar developed by Samsung Bioepis, in the Korean market. The product became available last Friday following its addition to the national reimbursement list.Xbryk is a biosimilar to Amgen’s Xgeva and is approved to prevent skeletal-related even
www.koreabiomed.com
August 4, 2025 at 2:00 AM
"Boryung launches Samsung Bioepis' bone cancer biosimilar with storage edge over Amgen's Xgeva"
#Caregiving #Healthcare #ElderCare #MedSky
#Caregiving #Healthcare #ElderCare #MedSky
"Samsung Bioepis hands Amgen's bone drug copycat to Boryung in Korea deal"
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
Samsung Bioepis hands Amgen's bone drug copycat to Boryung in Korea deal
Samsung Bioepis is handing its newest denosumab copycat, Xbryk, a biosimilar to Amgen’s bone cancer drug Xgeva, to longtime partner Boryung under an exclusive Korea-only licensing deal announced Wednesday.Samsung Bioepis will make and supply the drug while Boryung, described as Korea’s “top-selling
www.koreabiomed.com
July 5, 2025 at 4:54 PM
"Samsung Bioepis hands Amgen's bone drug copycat to Boryung in Korea deal"
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
"Samsung Bioepis hands Amgen's bone drug copycat to Boryung in Korea deal"
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
Samsung Bioepis hands Amgen's bone drug copycat to Boryung in Korea deal
Samsung Bioepis is handing its newest denosumab copycat, Xbryk, a biosimilar to Amgen’s bone cancer drug Xgeva, to longtime partner Boryung under an exclusive Korea-only licensing deal announced Wednesday.Samsung Bioepis will make and supply the drug while Boryung, described as Korea’s “top-selling
www.koreabiomed.com
July 5, 2025 at 4:47 PM
"Samsung Bioepis hands Amgen's bone drug copycat to Boryung in Korea deal"
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
"Samsung Bioepis hands Amgen's bone drug copycat to Boryung in Korea deal"
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
Samsung Bioepis hands Amgen's bone drug copycat to Boryung in Korea deal
Samsung Bioepis is handing its newest denosumab copycat, Xbryk, a biosimilar to Amgen’s bone cancer drug Xgeva, to longtime partner Boryung under an exclusive Korea-only licensing deal announced Wednesday.Samsung Bioepis will make and supply the drug while Boryung, described as Korea’s “top-selling
www.koreabiomed.com
July 5, 2025 at 4:41 PM
"Samsung Bioepis hands Amgen's bone drug copycat to Boryung in Korea deal"
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky